Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 27777 | 27.89 |
09:34 ET | 735 | 27.96 |
09:36 ET | 2014 | 27.83 |
09:38 ET | 516 | 27.91 |
09:39 ET | 966 | 27.8808 |
09:41 ET | 2875 | 27.8409 |
09:43 ET | 600 | 27.85 |
09:45 ET | 2958 | 27.86 |
09:48 ET | 4476 | 27.82 |
09:50 ET | 700 | 27.86 |
09:52 ET | 1290 | 27.885 |
09:54 ET | 1545 | 27.89 |
09:56 ET | 1777 | 27.93 |
09:57 ET | 700 | 27.93 |
09:59 ET | 900 | 27.94 |
10:01 ET | 2504 | 27.9201 |
10:03 ET | 2564 | 27.93 |
10:06 ET | 4042 | 27.905 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.5B | 11.0x | +1.83% |
Amneal Pharmaceuticals Inc | 1.9B | -19.8x | --- |
Catalent Inc | 10.1B | -7.8x | --- |
Jazz Pharmaceuticals PLC | 6.9B | 18.2x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Prestige Consumer Healthcare Inc | 3.6B | -43.4x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.5B |
---|---|
Revenue (TTM) | $2.4B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.01% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.47 |
EPS | $2.54 |
Book Value | $14.61 |
P/E Ratio | 11.0x |
Price/Sales (TTM) | 7.0 |
Price/Cash Flow (TTM) | 9.7x |
Operating Margin | 63.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.